Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Bioteknik |
On 27 February 2019, Endpoints News published an article about Follicum: "Follicum, a Swedish biotech company born to find a treatment for hair loss, now has diabetes in its crosshairs".
Read the article (https://endpts.com/follicum-a-swedish-biotech-company-born-to-find-a-treatment-for-hair-loss-now-has-diabetes-in-its-crosshairs/)
For further information, please contact:
Jan Alenfall - CEO, Follicum AB
Telephone: +46 46 19 21 97
Email: info@follicum.com
About Follicum AB
Follicum is a biotech company focusing on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014.